Opportunity Information: Apply for PA 16 243
Apply for PA 16 243
- The HHS-NIH11 in the health sector is offering a public funding opportunity titled "Novel Approaches to Understanding, Preventing and Treating Lyme Disease and Tick-borne Coinfections (R01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.846, 93.855, 93.856,.
- This funding opportunity was created on May 09, 2016 and posted on May 09, 2016.
- Applicants must submit their applications by Sep 07, 2019. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For profit organizations other than small businesses, Small businesses, Others (see text field entitled Additional Information on Eligibility for clarification).
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The funding opportunity titled "Novel Approaches to Understanding, Preventing and Treating Lyme Disease and Tick-borne Coinfections (R01)" (Funding Opportunity Number PA 16-243) is a discretionary NIH grant program designed to support full-scale, hypothesis-driven research projects that move the science forward on Lyme disease and other infections spread by Ixodes ticks. It was posted on May 9, 2016 (creation date and posted date both May 9, 2016), with an application closing date of September 7, 2019. The awarding agency is within the U.S. Department of Health and Human Services under NIH (listed as HHS-NIH11). The activity sits in the health research category and is associated with CFDA numbers 93.846, 93.855, and 93.856, which generally indicate NIH research assistance programs tied to infectious disease, allergy, and immunology-related portfolios.
At its core, the FOA is aimed at improving the overall understanding of Lyme disease and Ixodes tick-borne coinfections by encouraging novel, rigorous studies across a broad set of scientific domains. The announcement explicitly calls for research that addresses (1) pathogenesis, meaning how Borrelia burgdorferi and other tick-borne pathogens cause disease and how infection progresses in the body; (2) host response, covering immune mechanisms, inflammation, and other physiological responses that influence disease severity, persistence, and outcomes; (3) disease transmission, including how pathogens move between ticks, animal reservoirs, and humans, and what ecological or behavioral factors shape that process; (4) vector biology and natural history, which can include tick life cycle biology, tick-pathogen interactions, geographic spread, environmental drivers, and the role of wildlife hosts; (5) vaccines, spanning antigen discovery, immune correlates of protection, vaccine platform development, and strategies that could protect humans or interrupt transmission; (6) diagnostics, including improvements in sensitivity and specificity, earlier detection, differentiation of active infection versus prior exposure, and tests that can better detect coinfections; and (7) therapeutics, which can include new antimicrobial approaches, host-directed therapies, treatment optimization, and interventions targeted at acute disease or complications associated with infection.
Because this is an R01 mechanism, the intent is to fund substantial research efforts with clear aims, strong preliminary rationale (as appropriate for the project), and a realistic plan for generating impactful results. Projects can be basic, translational, or applied in nature as long as they meaningfully advance knowledge or tools related to Lyme disease and Ixodes-borne coinfections. The breadth of the topic areas signals that NIH is interested not only in clinical questions, but also in the upstream biology of ticks and pathogens, the ecological context that drives human risk, and the pipeline from discovery to practical countermeasures like better diagnostics, vaccines, and treatments. The FOA does not specify an award ceiling, expected number of awards, or other funding totals in the provided source data, which typically means applicants would need to consult the full announcement and institute-specific guidance to understand budget expectations and paylines.
Eligibility is broad and includes most major categories of U.S. research performers and public-serving entities. Eligible applicants listed include state, county, and city or township governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments and other tribal organizations; public housing authorities/Indian housing authorities; nonprofit organizations with or without 501(c)(3) status (other than institutions of higher education); for-profit organizations other than small businesses; small businesses; and additional unspecified eligible entities referenced in an "Additional Information on Eligibility" field. In practice, that breadth indicates the program is open to academic researchers, medical and public health institutions, nonprofits, and industry partners, reflecting the reality that progress on tick-borne diseases often depends on cross-sector collaboration, from field ecology and vector surveillance to immunology, diagnostic development, and therapeutic testing.
In summary, PA 16-243 is a research-focused NIH R01 opportunity meant to catalyze innovative work on Lyme disease and Ixodes tick-borne coinfections across the full spectrum of discovery and intervention development. It encourages applicants to tackle core gaps in understanding how these infections are transmitted and cause illness, while also pushing forward practical solutions such as improved diagnostics, vaccines, and therapeutics that could reduce disease burden and improve patient outcomes.
Frequently Asked Questions (FAQs)
What is the title of this funding opportunity?
The funding opportunity is titled "Novel Approaches to Understanding, Preventing and Treating Lyme Disease and Tick-borne Coinfections (R01)."
What is the Funding Opportunity Number (FOA number)?
The Funding Opportunity Number is PA 16-243.
What type of grant mechanism is this?
This opportunity uses the NIH R01 mechanism, which is intended to support full-scale, hypothesis-driven research projects.
Which agency is offering this grant?
The awarding agency is within the U.S. Department of Health and Human Services (HHS), under the National Institutes of Health (NIH), listed as HHS-NIH11.
When was this opportunity posted?
The opportunity was posted on May 9, 2016. The creation date and posted date are both May 9, 2016.
When is (or was) the application closing date?
The application closing date listed is September 7, 2019.
What research area or category does this opportunity fall under?
The activity is in the health research category and focuses on Lyme disease and other infections spread by Ixodes ticks.
What CFDA numbers are associated with this opportunity?
The opportunity is associated with CFDA numbers 93.846, 93.855, and 93.856, which generally align with NIH research assistance programs connected to infectious disease, allergy, and immunology-related portfolios.
What is the overall purpose of this FOA?
The FOA is designed to support novel, rigorous studies that improve understanding of Lyme disease and Ixodes tick-borne coinfections and that move the science forward across discovery and intervention development.
What kinds of research projects does this FOA support?
It supports full-scale, hypothesis-driven research projects that can be basic, translational, or applied, as long as they meaningfully advance knowledge or tools related to Lyme disease and Ixodes-borne coinfections.
Is the FOA limited to clinical research only?
No. The FOA encourages research not only on clinical questions, but also on upstream biology of ticks and pathogens, ecological drivers of human risk, and the pathway from discovery to practical countermeasures.
What topic areas are explicitly encouraged by the FOA?
The announcement explicitly calls for research addressing: (1) pathogenesis, (2) host response, (3) disease transmission, (4) vector biology and natural history, (5) vaccines, (6) diagnostics, and (7) therapeutics.
What does "pathogenesis" mean in the context of this FOA?
Pathogenesis refers to how Borrelia burgdorferi and other tick-borne pathogens cause disease and how infection progresses in the body.
What does "host response" cover under this FOA?
Host response covers immune mechanisms, inflammation, and other physiological responses that influence disease severity, persistence, and outcomes.
What does the FOA mean by "disease transmission" research?
Disease transmission research includes how pathogens move between ticks, animal reservoirs, and humans, and what ecological or behavioral factors shape that process.
What is included under "vector biology and natural history"?
This can include tick life cycle biology, tick-pathogen interactions, geographic spread, environmental drivers, and the role of wildlife hosts.
What vaccine-related work does the FOA encourage?
The FOA encourages vaccine research such as antigen discovery, identifying immune correlates of protection, vaccine platform development, and strategies that could protect humans or interrupt transmission.
What diagnostic-related work does the FOA encourage?
The FOA encourages improvements in diagnostic sensitivity and specificity, earlier detection, differentiating active infection versus prior exposure, and tests that can better detect coinfections.
What therapeutic-related work does the FOA encourage?
The FOA encourages new antimicrobial approaches, host-directed therapies, treatment optimization, and interventions targeted at acute disease or complications associated with infection.
Does the FOA support work on coinfections spread by Ixodes ticks?
Yes. A central focus is Lyme disease and other infections spread by Ixodes ticks, including Ixodes tick-borne coinfections.
Does this FOA require a particular research stage (basic vs translational vs applied)?
No specific stage is required in the provided information. Projects may be basic, translational, or applied, as long as they advance knowledge or tools related to Lyme disease and Ixodes-borne coinfections.
Does the FOA specify an award ceiling or total funding amount?
No. In the provided source information, the FOA does not specify an award ceiling, expected number of awards, or funding totals.
Does the FOA specify how many awards NIH expects to make?
No. The provided information does not include an expected number of awards.
Who is eligible to apply?
Eligibility is broad and includes state, county, and city or township governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments and other tribal organizations; public housing authorities/Indian housing authorities; nonprofit organizations with or without 501(c)(3) status (other than institutions of higher education); for-profit organizations other than small businesses; small businesses; and other eligible entities referenced under "Additional Information on Eligibility."
Are for-profit organizations eligible?
Yes. For-profit organizations other than small businesses are listed as eligible, and small businesses are also listed as eligible.
Are nonprofit organizations eligible?
Yes. Nonprofit organizations with or without 501(c)(3) status (other than institutions of higher education) are listed as eligible.
Are universities and colleges eligible?
Yes. Public and state-controlled institutions of higher education and private institutions of higher education are listed as eligible.
Are governmental entities eligible to apply?
Yes. State governments, county governments, city or township governments, special district governments, and independent school districts are listed as eligible applicants.
Are tribal governments and tribal organizations eligible?
Yes. Federally recognized Native American tribal governments and other tribal organizations are listed as eligible.
Are public housing authorities eligible?
Yes. Public housing authorities/Indian housing authorities are listed as eligible applicants.
What does the FOA suggest about collaboration across sectors?
The broad eligibility categories suggest the program is open to a wide range of applicants (academia, public health and medical institutions, nonprofits, and industry partners), reflecting that progress on tick-borne diseases often benefits from cross-sector collaboration.
What kinds of scientific domains does NIH appear to be interested in for this FOA?
The FOA signals interest across domains such as immunology, pathogen biology, tick/vector biology, ecology and environmental drivers, transmission dynamics, diagnostics development, vaccine development, and therapeutic approaches.
What does "full-scale, hypothesis-driven" imply about the expected project scope?
It implies substantial research efforts with clear aims and a realistic plan for generating impactful results, consistent with the R01 mechanism.
Browse more opportunities from the same category: Health
Next opportunity: Pollinators of the Endangered Dwarf Bear Poppy
Previous opportunity: NOTICE OF INTENT: Create Mobile Accessibility to Enhance Visitor Experience of Natural Communities
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PA 16 243
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PA 16 243) also looked into and applied for these:
| Funding Opportunity |
|---|
| Nathan Shock Centers Coordinating Center (U24) Apply for RFA AG 17 008 Funding Number: RFA AG 17 008 Agency: HHS-NIH11 Category: Health Funding Amount: $350,000 |
| Informatics Methodology and Secondary Analyses to Explore Shared Immunology Study Data in ImmPort (UH2) Apply for PAR 16 253 Funding Number: PAR 16 253 Agency: HHS-NIH11 Category: Health Funding Amount: $200,000 |
| Ryan White HIV/AIDS Program Building Care and Prevention Capacity: Addressing the HIV Care Continuum in Southern Metropolitan Areas Apply for HRSA 16 187 Funding Number: HRSA 16 187 Agency: HHS-HRSA Category: Health Funding Amount: Case Dependent |
| From Association to Function in the Alzheimers Disease Post Genomics Era (R21) Apply for RFA AG 17 011 Funding Number: RFA AG 17 011 Agency: HHS-NIH11 Category: Health Funding Amount: $200,000 |
| Centers of Research Translation (CORT) (P50) Apply for RFA AR 17 001 Funding Number: RFA AR 17 001 Agency: HHS-NIH11 Category: Health Funding Amount: $1,000,000 |
| Mechanisms of Mycobacterial-Induced Immunity in HIV-Infected and Uninfected Individuals to Inform Tuberculosis Vaccine Design (R01) Apply for PAR 16 254 Funding Number: PAR 16 254 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
| Mississippi Delta Health Collaborative Apply for CDC RFA DP16 1612 Funding Number: CDC RFA DP16 1612 Agency: HHS-CDC-NCCDPHP Category: Health Funding Amount: $3,150,000 |
| Public Health Preparedness and Response (PHPR) Cooperative Agreement for All-Hazards Public Health Emergencies: Zika 2016 Apply for CDC RFA TP16 1602 Funding Number: CDC RFA TP16 1602 Agency: HHS-CDC-OPHPR Category: Health Funding Amount: $5,000,000 |
| Grants for Early Medical/Surgical Subspecialists' Transition to Aging Research (GEMSSTAR) (R03) Apply for RFA AG 17 012 Funding Number: RFA AG 17 012 Agency: HHS-NIH11 Category: Health Funding Amount: $75,000 |
| From Association to Function in the Alzheimers Disease Post Genomics Era (R01) Apply for RFA AG 17 010 Funding Number: RFA AG 17 010 Agency: HHS-NIH11 Category: Health Funding Amount: $350,000 |
| Establishment of Centers of Excellence in Refugee Health Apply for CDC RFA CK15 150302CONT16 Funding Number: CDC RFA CK15 150302CONT16 Agency: HHS-CDC-NCEZID Category: Health Funding Amount: Case Dependent |
| Learning Collaboratives for Advanced Business Acumen Skills Apply for HHS 2016 ACL CIP PPBA 0181 Funding Number: HHS 2016 ACL CIP PPBA 0181 Agency: HHS-ACL Category: Health Funding Amount: $500,000 |
| Creutzfeldt - Jakob Disease (CJD) Support, Education, and Awareness Projects as Apply for CDC RFA CK15 150402CONT16 Funding Number: CDC RFA CK15 150402CONT16 Agency: HHS-CDC-NCEZID Category: Health Funding Amount: Case Dependent |
| Environmental Sampling with NAU for High Consequence Pathogens Apply for CDC RFA CK16 1606 Funding Number: CDC RFA CK16 1606 Agency: HHS-CDC-NCEZID Category: Health Funding Amount: $300,000 |
| Children’s Hospitals Graduate Medical Education (CHGME) Payment Program Apply for HRSA 17 006 Funding Number: HRSA 17 006 Agency: HHS-HRSA Category: Health Funding Amount: Case Dependent |
| Jurisdictional Approach to Curing Hepatitis C Among HIV/HCV Coinfected People of Color - Evaluation and Technical Assistance Center Apply for HRSA 16 188 Funding Number: HRSA 16 188 Agency: HHS-HRSA Category: Health Funding Amount: Case Dependent |
| Inclusion of Mobile/e-Consents for Alzheimer's Disease Research (Admin Supp) Apply for PA 16 259 Funding Number: PA 16 259 Agency: HHS-NIH11 Category: Health Funding Amount: $100,000 |
| Jurisdictional Approach to Curing Hepatitis C among HIV/HCV Coinfected People of Color – Jurisdictional Sites Apply for HRSA 16 189 Funding Number: HRSA 16 189 Agency: HHS-HRSA Category: Health Funding Amount: Case Dependent |
| Reducing the Duration of Untreated Psychosis in the United States (R01) Apply for PAR 16 265 Funding Number: PAR 16 265 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
| Reducing the Duration of Untreated Psychosis in the United States (R34) Apply for PAR 16 264 Funding Number: PAR 16 264 Agency: HHS-NIH11 Category: Health Funding Amount: $225,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PA 16 243", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.